Tag, you are it: A two-step approach to treating patients with multiple myeloma shows promise

December 09, 2001

Fred Hutchinson Cancer Research Center investigator presents preliminary study results at the American Society of Hematology Meeting in Orlando, Fla.

Using a tag-team approach, researchers believe they may be able to increase survival for patients with multiple myeloma. In a multicenter study led by Dr. David Maloney at the Fred Hutchinson Cancer Research Center in Seattle, it was shown that by combining standard high-dose therapy and autologous stem-cell "rescue" with a procedure known as "mini-transplantation" from a sibling, that transplant-related toxicities could be reduced and survival increased for people diagnosed with multiple myeloma. Preliminary results from the study will be presented at the 43rd annual meeting of the American Society of Hematology in Orlando, Fla.

The phase II study involved 41 patients, ages 39-71, who had advanced-stage multiple myeloma. All patients had previously undergone chemotherapy to treat their disease. Now, more than four hundred days after undergoing treatment, 85 percent of these people are still surviving, leading researchers to believe that this two-step treatment option has real potential as a cure for this disease. The lead patients are now three years out from transplant without evidence of disease. "Harnessing the power of the donor immune system to eradicate cancer with a lower toxicity is exciting and promising," says Maloney. The process, called allogeneic immunotherapy has also been successfully used for the treatment of patients with leukemia, lymphoma and a solid tumor called renal cell cancer."

The first step in the two-step process is high-dose chemotherapy followed by a transplant using the patient's own stem cells to reduce the disease burden. Typically, patients undergoing high-dose chemotherapy often experience a number of complications that can be life threatening. The second step, one to three months later, is the mini-transplant procedure, during which the patient undergoes low-dose radiation followed by an infusion of stem cells from a matched brother or sister.

The concept of mini-transplantation was developed in preclinical studies at the Fred Hutchinson Cancer Research Center in a the group led by Dr. Rainer Storb, head of transplantation biology at the Hutchinson Center.

Maloney and colleagues believe that by separating the high-dose conditioning regimen from the immunotherapeutic effect of mini-transplantation, there is a decrease in death due to the transplant related complications. Mini-transplantation establishes an initial tolerance between the donor cells and the patient's own tissues, a phenomenon called "mixed hematopoietic chimerism." Later, the new immune system of the donor replaces the patient's bone marrow. In the process, the donor immune system attacks the malignant myeloma cells, through a graft-versus-myeloma effect.

For the patients, the treatment experience in step two is dramatically different from step one, requiring less hospitalization with most undergoing the procedure in an outpatient setting. Clinic visits are two to three times a week the first month and once or twice a week for the duration of their recovery period. Also, treatment-related toxicities are mild to moderate. The low-dose radiation does not cause the usual severe side effects associated with a high-dose transplant such as nausea, vomiting or diarrhea, and patients do not lose their hair. More significantly, blood counts never drop below levels the body needs to fight infections and stop bleeding.

Multiple myeloma is a cancer of the bone marrow that most often affects older adults. Depending on the stage of the disease at diagnosis, survival time ranges between three and five years. Upon diagnosis, the first goal for treatment is to relieve symptoms. There is no known cure to date.

Over the years, bone-marrow transplantation has been proven as a successful treatment for leukemia, lymphoma and a number of other blood and genetic disorders. While long-term survival after transplantation has increased significantly over the years and many people survive to live healthy and productive lives, a number of people are unable to tolerate the rigors of the therapy, especially people over age 50. It is known that the toxic effects of conventional stem-cell transplants are a major problem for older patients as well as younger patents with medical problems. Mini-transplantation offers options for these people.

Fred Hutchinson Cancer Research Center is recognized as a leader in cancer research. Its objective is to eliminate cancer as a cause of human suffering and death. The Hutchinson Center conducts research of the highest standards to improve prevention, diagnosis and treatment of cancer and related diseases. The Center's clinical research is focused on improving therapies for adults and children through the conduct of clinical trials, many involving bone-marrow and stem-cell transplantation.
-end-
Researchers from four leading cancer centers, nationally and internationally, participated in this study, including the Fred Hutchinson Cancer Research Center, Veterans Administration Medical Center in Seattle, the City of Hope Medical Center in Duarte, Cal.; Stanford University Medical Center, and the University of Leipzig in Germany.

Fred Hutchinson Cancer Research Center

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.